KPV
A short peptide discussed for gut and skin inflammation.
The short version
- Why people discuss it
- Discussed for gut and skin inflammation. The research already collected here is mainly laboratory and animal work; it does not establish a human treatment benefit.
- What it is
- A three-amino-acid peptide. Oral, topical and injectable formulations are separate contexts, with no established conversion between them.
- Biggest caution
- FDA says it has not identified human exposure data for KPV drug products and lacks information needed to determine human harm.
- Stack context
- Included in KLOW alongside BPC-157, TB-500 and GHK-Cu. A result for KPV alone is not evidence for the blend.
Dose and frequency reference
Reference only — not a recommendation. Amounts describe source-specific community examples, selected study regimens or the named product label. They do not establish safety, effectiveness, product identity, or a suitable dose for any person. Never convert mg, mcg, or IU into syringe “units” without the exact product concentration.
Source agreement describes reported practice, not clinical validation.
Subcutaneous injection
Community reference · Not clinical guidance- Amount
- 200–500 mcg
- Frequency
- Once daily
- Duration / phase
- 4–8 weeks
Amount and daily frequency overlap the two new sources. Peptidepedia describes 4–8 weeks, while PeptideDosages extends to 8–12 weeks. Oral amounts belong to a separate route; no human dose-finding is established. Reference only; this does not establish safety, effectiveness or individual suitability.
Community source · reviewed 2026-09-27Compare reported schedules
Saved source material reviewed 2026-09-27. Multiple pages from one publisher count as one source family; agreement does not establish what most people use. SC means subcutaneous; IM intramuscular; IP intraperitoneal.
- PeptideDosages — saved source reviewed September 27, 2026
200–500 mcg SC daily; 8–12 weeks, optional 16.
- Peptidepedia — saved source reviewed September 27, 2026
200–500 mcg SC daily for 4–8 weeks; oral 500–1,500 mcg/day, sometimes divided twice daily.
Evidence & sources · Preclinical evidence
Community references document claims and reported practices. They are not clinical evidence. Some references contain supplier promotions or market treatment; their commercial context is identified in the source label.
- Preferred Regen: four-peptide stack discussion (clinic marketing)Community reference · Checked 2026-09-12
- Peptide Dosing Protocols (affiliate-supported reference)Community reference · Checked 2026-09-12
- FDA: peptide compounding safety concernsRegulatory source · Checked 2026-09-12
- Existing KPV cell and mouse studyExisting research · Checked 2026-09-08
- PeptideDosages — saved source reviewed September 27, 2026Community reference · Checked 2026-09-27
- Peptidepedia — saved source reviewed September 27, 2026Community reference · Checked 2026-09-27